Tremendous advances have been made in the treatment of multiple myeloma in recent decades with a growing armamentarium of drugs and a better molecular understanding of disease. These advances have resulted in more than a doubling in overall survival. As a community, we remain challenged by those high-risk patients who appear to be benefiting less from recent developments as compared to their standard risk counterparts, by the broad array of treatment options and the sequencing thereof, and by the role of stem cell transplant and maintenance in this complicated landscape.
Dr. Angela Dispenzieri will focus on definitions of and strategies to manage newly diagnosed high-risk patients. This discussion will be focused in the context of what is known and what we need to learn about these challenging patients.
Dr. Noopur Raje will summarize what is known about sequencing non-transplant therapies in patients with active disease. As new drugs are approved and new regimens described, there is a dizzying array of therapeutic strategies from which to choose. She will put these options into context and provide expert guidance.
Dr. Philip McCarthy will discuss the role of high-dose therapy with stem cell transplant and maintenance therapy in the current era. Despite the approval of additional myeloma therapies each year, stem cell transplant still plays an important role for patients with multiple myeloma. As more drugs emerge, other opportunities for post-transplant maintenance also bring promise.
Angela Dispenzieri, MD
Philip L. McCarthy, MD
Noopur Raje, MD
Active, International, Emeritus, and Honorary Members
Associate, International Associate, Student, and Resident Members